Pfizer acquires Baxter vaccines for $635m

Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.

Under the agreement, Pfizer will also acquire part of Baxter’s manufacturing plant in Orth, Austria.

The two vaccines are NeisVac-C, which helps protect against meningitis, and FSME-IMMUN/TicoVac, a vaccine for tick-borne encephalitis.

“Every day people of all ages benefit from safe and effective vaccines,” said Pfizer’s vaccines president Susan Silbermann.

“Through this acquisition, we will add two high-quality and life-saving vaccines that bring scale and depth to our portfolio.”

The transaction is expected to close by the end of 2014.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

EC signs contract with Pfizer to access watershed vaccine

12 November 2020 The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.

Americas

Baxter sues B.Braun in revived kidney treatment patent dispute

16 November 2020 American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.